Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J. Landovitz, Sheldon D. Fields, Leslie Cottle et al.|New England Journal of Medicine|2021Cited by 847
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021Steven G. Deeks, Josephine Nabukenya, Nancie M. Archin et al.|Nature Medicine|2021Cited by 367
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected RecipientsChristine M. Durand, Niraj M. Desai, Mary G. Bowring et al.|Annals of Internal Medicine|2018Cited by 295
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meetingBoris Jülg, Bruce D. Walker, Lynda Dee et al.|The Lancet HIV|2019Cited by 206
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J. Landovitz, Joseph J. Eron, Sue Li et al.|PLoS Medicine|2018Cited by 171